Can Cencora (COR) Sustain Its Margin Gains While Accepting Slower Revenue Growth?
Cencora, Inc. has already reported fiscal 2026 second-quarter results, posting sales of US$78.36 billion and net income of US$1.64 billion, while slightly raising adjusted EPS guidance but trimming full-year revenue growth expectations to a 4%–6% range.
The quarter highlighted improving profitability helped by the OneOncology acquisition and margin expansion, even as U.S. Healthcare Solutions faced headwinds from pricing pressure, customer mix shifts and slower growth in key drug...
Generated by Pulse AI, Glideslope's proprietary engine for interpreting market sentiment and economic signals. For informational purposes only — not financial advice.
